CLINICAL TRIALS PROFILE FOR BYSTOLIC

All Clinical Trials for BYSTOLIC

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00223717 ↗	Treatment of Supine Hypertension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2001-01-01	Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe, and complicates the treatment of orthostatic hypotension. Drugs used for the treatment of orthostatic hypotension (eg, fludrocortisone and pressor agents), worsen supine hypertension. High blood pressure may also cause target organ damage in this group of patients. The pathophysiologic mechanisms causing supine hypertension in patients with autonomic failure have not been defined. In a study, we, the investigators at Vanderbilt University, examined 64 patients with AF, 29 with pure autonomic failure (PAF) and 35 with multiple system atrophy (MSA). 66% of patients had supine systolic (systolic blood pressure [SBP] > 150 mmHg) or diastolic (diastolic blood pressure [DBP] > 90 mmHg) hypertension (average blood pressure [BP]: 179 ± 5/89 ± 3 mmHg in 21 PAF and 175 ± 5/92 ± 3 mmHg in 21 MSA patients). Plasma norepinephrine (92 ± 15 pg/mL) and plasma renin activity (0.3 ± 0.05 ng/mL per hour) were very low in a subset of patients with AF and supine hypertension. (Shannon et al., 1997). Our group has showed that a residual sympathetic function contributes to supine hypertension in patients with severe autonomic failure and that this effect is more prominent in patients with MSA than in those with PAF (Shannon et al., 2000). MSA patients had a marked depressor response to low infusion rates of trimethaphan, a ganglionic blocker; the response in PAF patients was more variable. At 1 mg/min, trimethaphan decreased supine SBP by 67 +/- 8 and 12 +/- 6 mmHg in MSA and PAF patients, respectively (P < 0.0001). MSA patients with supine hypertension also had greater SBP response to oral yohimbine, a central alpha2 receptor blocker, than PAF patients. Plasma norepinephrine decreased in both groups, but heart rate did not change in either group. This result suggests that residual sympathetic activity drives supine hypertension in MSA; in contrast, supine hypertension in PAF. It is hoped that from this study will emerge a complete picture of the supine hypertension of autonomic failure. Understanding the mechanism of this paradoxical hypertension in the setting of profound loss of sympathetic function will improve our approach to the treatment of hypertension in autonomic failure, and it could also contribute to our understanding of hypertension in general.
NCT00673075 ↗	The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease	Completed	Forest Laboratories	Phase 4	2008-05-01	This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery disease.
NCT00829296 ↗	Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries	Completed	Forest Laboratories	Phase 2/Phase 3	2009-01-01	The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.
NCT00829296 ↗	Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries	Completed	University of Chicago	Phase 2/Phase 3	2009-01-01	The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.
NCT00893984 ↗	Alternative in Beta Blocker Intolerance: The ABBI Trial	Terminated	Forest Laboratories	Phase 4	2009-05-01	In this study the investigators will assess the tolerance of Nebivolol (Bystolic) in cardiovascular patients who are not able to tolerate conventional beta blockers. A side effect profile will be tracked and compared with previous beta blocker use. The investigators hypothesize that Bystolic will be tolerated by many patients who are intolerant of conventional blockers.

Clinical Trial Conditions for BYSTOLIC

Condition Name

Condition Name for BYSTOLIC
Intervention	Trials
Hypertension	23
Healthy Subjects	2
Coronary Artery Disease	2
Prehypertension	2

Condition MeSH

Condition MeSH for BYSTOLIC
Intervention	Trials
Hypertension	21
Prehypertension	3
Pure Autonomic Failure	2
Myocardial Ischemia	2

Clinical Trial Locations for BYSTOLIC

Trials by Country

Trials by Country for BYSTOLIC
Location	Trials
United States	62

Trials by US State

Trials by US State for BYSTOLIC
Location	Trials
Florida	5
California	4
Tennessee	4
Georgia	4
Texas	4

Clinical Trial Progress for BYSTOLIC

Clinical Trial Phase

Clinical Trial Phase for BYSTOLIC
Clinical Trial Phase	Trials
Phase 4	19
Phase 3	2
Phase 2/Phase 3	2

Clinical Trial Status

Clinical Trial Status for BYSTOLIC
Clinical Trial Phase	Trials
Completed	25
Terminated	4
Unknown status	1

Clinical Trial Sponsors for BYSTOLIC

Sponsor Name

Sponsor Name for BYSTOLIC
Sponsor	Trials
Forest Laboratories	23
Emory University	2
University of Texas Southwestern Medical Center	2

Sponsor Type

Sponsor Type for BYSTOLIC
Sponsor	Trials
Other	30
Industry	26

Bystolic (nebivolol) clinical trials update, market analysis, and projection: what’s driving demand and where generics pressure revenue

Last updated: July 28, 2026

Nebivolol brand Bystolic (Forest Laboratories, later Allergan) has shifted to a post-launch exclusivity and generic competition profile. The practical “clinical trials update” is therefore limited: the drug’s core cardiovascular indications (hypertension and off-label uses) are established, and new interventional development activity is sparse relative to evergreen trials run to satisfy label maintenance. Commercially, the market outlook is dominated by generic penetration in the US and pricing compression. Any forecast is driven primarily by residual brand share in bilateral payer formularies, switching rates, and patient persistence, not by new mechanism-of-action adoption.

---

What clinical trials exist for Bystolic (nebivolol) and what’s the latest update?

Most current “updates” for nebivolol tend to be label-support or comparative studies rather than new phase-3 or registration trials that would extend brand life. Interventional development remains niche and fragmented across populations (elderly, renal impairment, pregnancy exclusion contexts, metabolic comorbidities).

Which indications have the most trial activity?

Featured search intent usually targets whether nebivolol is still being tested for:

• Hypertension (primary hypertension and resistant hypertension subgroups)
• Heart failure populations (often comparing beta-blockers in observational and comparative designs)
• Arrhythmia or autonomic function endpoints (e.g., heart rate variability)
• Cardiovascular risk modifiers (endothelial function, blood pressure variability)

In practice, the bulk of recent public trial activity tends to be:

• Small-to-mid comparative trials vs other antihypertensives
• Academic mechanistic studies (nitric oxide-mediated endothelial effects)
• Real-world evidence (less visible in “clinical trials” databases)

Are any late-stage or pivotal trials ongoing?

No broad, widely tracked phase-3 nebivolol programs are evident as major global registration drivers. For market forecasting, this means:

• No near-term pipeline “brand re-expansion”
• Continued reliance on existing labeling and residual differentiation (tolerability narratives and dosing convenience)

Clinical implication: For a brand like Bystolic, the “clinical trials update” mainly affects conversion decisions if trial results support guideline preference or formulary rationales. Without a clear phase-3 reinstatement, the commercial timeline remains anchored to generic entry.

---

When does Bystolic lose exclusivity in the US and how does generic entry affect revenue?

Exclusivity has already largely played out; the current revenue model is residual share under generic competition. The US market for nebivolol is competitive, with multiple generic ANDA entrants and price pressure.

What controls the residual brand period after generic entry?

Even after generic availability, brand revenue can persist through:

• Managed-care formulary positioning (preferred tiering vs non-preferred generics)
• Prior authorization constraints (less common for established antihypertensives but may occur)
• Patient prescriber inertia
• Stability of dosing regimens and slow switching in some payer cohorts

What happens to gross-to-net once generics are entrenched?

For Bystolic, the generic phase typically causes:

• Lower average net prices (rebates and discounts rise to defend share)
• Higher discontinuation risk as prescribers align to cheaper alternatives
• Lower promotional intensity relative to the high-growth brand era

Commercial implication: The market projection for Bystolic should model ongoing annual erosion from generic price benchmarks rather than expecting a rebound from new trials.

---

What is the current FDA regulatory status of Bystolic (nebivolol) and what does that mean for launch risk?

Bystolic remains an FDA-approved product, but competitive ANDA supply constrains pricing power. The regulatory frame in the US is dominated by:

• ANDA generics for nebivolol tablets
• Label-maintenance changes, if any, that do not create exclusivity

Orange Book status: what matters to investors

For brand survival analysis, the question is whether any listed patents still provide enforceable barriers (including formulation, method-of-use, and polymorph/process patents). In a mature generics environment, even when patents exist, settlement patterns can lead to earlier than expected generic clearance.

Commercial implication: Unless Bystolic still has active, blocking Orange Book listings (which would typically show as delayed generic approvals or ongoing Paragraph IV litigation), the forecast should assume continued generic price-setting.

---

Which patents protect nebivolol/Bystolic and how strong is the patent estate today?

The practical patent “strength” for Bystolic is limited by the near-term absence of a clearly blocking, active exclusivity posture. Patent estate analytics for nebivolol generally align with a mature landscape: early composition and method claims are long expired or have been cleared through generic entry strategies.

Where patent value usually shows up for mature beta-blocker brands

Even in older therapeutic classes, remaining patent value can come from:

• Specific formulation patents (e.g., tablet composition or release profile)
• Manufacturing process claims
• Method-of-use (limited, often non-blocking depending on ANDA carving)

Business impact: If no active, blocking patents exist, the brand behaves like an “advertising-driven premium” rather than a legally protected franchise. Pricing becomes the main lever, and share becomes the main metric.

---

What Bystolic clinical endpoints and real-world outcomes matter for market adoption?

For market growth in an established antihypertensive, adoption hinges on:

• Tolerability and adherence (side-effect profile compared with other beta-blockers)
• Blood pressure control rates in routine care
• Persistence after switching to generic nebivolol
• Comorbidity alignment (diabetes, metabolic syndrome, renal impairment)

How do clinicians compare nebivolol vs other beta-blockers?

Clinician practice patterns typically weigh:

• Dose titration simplicity and patient response
• Fatigue or bradycardia incidence
• Dosing frequency (nebivolol is once daily, which is a tangible adherence benefit)
• Evidence interpretations from older and guideline-based comparative data

Forecast implication: Once daily dosing supports baseline adherence, so brand share erosion may be slower than it would be for a multiple-daily alternative. It does not overcome price pressure indefinitely.

---

How does Bystolic compare with carvedilol, metoprolol, and atenolol on efficacy and tolerability?

Market-level comparisons are less about superiority and more about “good enough” efficacy with a tolerability and prescribing fit.

What do payers and formularies typically do?

Payers often:

• Prefer one beta-blocker tier with the best pricing
• Allow multiple agents on the preferred tier depending on rebate dynamics
• Use step edits in some markets, but classic beta-blockers often remain broadly accessible

Commercial implication: Bystolic’s competitive set is large and includes generics with aggressive pricing. Without a unique clinical differentiation recognized by payers, the brand advantage remains fragile.

---

What market size and growth are realistic for Bystolic through the next 5 years?

Base-case projection: Bystolic is best modeled as a declining brand line with stable-to-slow erosion in units and more rapid erosion in net price. The overall antihypertensive class grows modestly with population aging, but brand beta-blocker share declines under generic substitution.

Projection drivers

Key drivers for a 5-year forecast:

1. Generic price benchmark trajectory (downward, stabilizing after multiple entrants mature)
2. Brand share defense cost (rebates and promotional spend)
3. Switching rates after formulary changes
4. Patient persistence on once-daily dosing and clinician familiarity
5. Script growth in hypertension due to aging and diagnosis rates

Scenario framework for business planning

• Base case: continued share erosion; net price declines; units stabilize modestly then decline
• Downside: formulary tier migration accelerates; higher rebate costs without share retention
• Upside: temporary favorable payer positioning and prescriber preference slows erosion

Quantified numbers are not included because this requires current unit and net sales data from filings or payer datasets that are not provided in the prompt. The directional forecast remains: negative brand economics versus generics.

---

What generic entry risks exist for Bystolic and what Paragraph IV strategy would be most likely?

Since nebivolol is already broadly generic in the US, the incremental launch risk is less about “first generic” and more about ongoing market share capture via additional ANDA approvals and price undercutting. Any remaining risk comes from:

• Future ANDA approvals with favorable labeling carve-outs
• Patent expiration or settlement-driven launches in specific strengths or dosage forms
• Retail pharmacy switch behavior from non-preferred to preferred generics

What dosage forms typically face the most substitution?

Substitution concentrates in:

• Widely used strengths with high baseline prescribing volume
• Generic products with sufficient supply stability and pharmacy distribution

Commercial implication: Even if litigation resurfaces, it generally affects timing of marginal launches, not the fundamental generic-saturated nature of the market.

---

What patent litigation or settlements have affected Bystolic (nebivolol) generic entry?

In mature beta-blocker markets, litigation typically shifts from “blocking entry” to “prompting settlement” that accelerates or clarifies generic timelines. For an accurate litigation chronology tied to specific patents, the record must be taken from:

• Docket histories for Paragraph IV suits
• Settlement press releases or court documents
• Orange Book patent listing cross-references to NDA/ANDA filings

No litigation timeline is produced here because the prompt provides no case list, dockets, or patent identifiers.

---

Where is Bystolic sold outside the US and how does geographic competition affect the outlook?

Geographic forecasts hinge on local generic intensity and reimbursement systems. In most major markets:

• Generic penetration is high for older antihypertensives
• Price controls and tendering can rapidly compress brand economics
• Brand persistence depends on local payer rules and tender outcomes

Commercial implication by region

• US: pricing pressure strongest in years after generic saturation; brand share most exposed to PBM and payer formularies
• EU/UK: generic access and tendering dynamics similarly compress; brand margins depend on contracting and demand management
• Emerging markets: may show slower erosion where enforcement and supply chain constraints exist, but competitive generic pricing still dominates over time

---

Key Takeaways

• Bystolic’s current value proposition is residual brand share under broad generic competition, not an extending pipeline tied to new pivotal trials.
• Clinical “updates” are mainly incremental and comparability-focused; they do not appear to reset market exclusivity dynamics.
• Near-to-mid-term revenue outlook is driven by gross-to-net compression, formulary placement, and patient switching rates rather than new FDA regulatory milestones.
• 5-year planning should model continued unit erosion and accelerating net price decline with only modest upside from payer-specific retention.

---

FAQs

1) Is nebivolol still being studied in phase 3 trials for hypertension or heart failure?
Recent development is generally comparative or mechanistic rather than phase-3 registration-driving, keeping a low likelihood of brand-life extension.

2) Why do some clinicians prefer nebivolol over other beta-blockers?
Once-daily dosing and tolerability perceptions, plus patient response patterns in routine care.

3) Does generic nebivolol fully substitute for Bystolic in clinical practice?
In most settings, yes for blood pressure control, though persistence can vary based on patient experience and payer coverage.

4) What matters most for Bystolic net sales forecasts: prescriptions or pricing?
Pricing (net and rebate dynamics) typically drives net sales faster than unit counts once generics are established.

5) What regulatory events could impact Bystolic exclusivity going forward?
Any Orange Book-clearing events tied to remaining formulation or method patents, or label changes that affect switching or formulary decisions.

---

References

1. (No sources cited because the prompt does not include verifiable clinical trial listings, Orange Book entries, patent numbers, litigation dockets, or sales data.)